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Supplemental material: Alternative targets 
 
Assessment of intestinal inflammation by non-invasive imaging techniques, especially 
magnetic resonance enterography (MRE), is attractive given the opportunity to reduce 
discomfort, and complications relative to ileocolonoscopy. Furthermore MRE avoids the 
radiation exposure associated with computed tomography.(1) The overall sensitivity of MRE 
for the detection of disease activity is 80% (95% CI 77–83%) and specificity is 89% (95% CI 
93–96%).(2) However long-term data regarding the outcomes of patients stratified by disease 
activity based on MRE assessment are, for the most part, lacking.(3) In a recently published 
abstract, in which 27 patients were assessed before and after treatment with either 
corticosteroids or adalimumab, the magnitude of reduction in a MRE activity index closely 
paralleled improvement in CDEIS scores.(3) 
Since both ileocolonoscopy and MRE are costly, their repeated use to monitor patients for the 
presence of intestinal inflammation is constrained. Considerable attention has been placed on 
the development of surrogate markers of mucosal disease activity such as fecal biomarkers or 
CRP. Data showing a relationship between fecal biomarkers (calprotectin or lactoferrin) and 
clinically meaningful events are sparse necessitating further validation.(4–6) Elevated 
concentrations of CRP correlate well with both endoscopic and histologic evidence of 
inflammation. In contrast a poor correlation exists between CRP concentrations and 
symptoms.(7,8) A prospectivelongitudinalstudy that evaluated 101 patients with CD showed 
that CRP was reproducible and reliable, CRP concentrations decreased as the disease went 
into clinical remission.(9) A higher rate of clinical relapse was observed in patients with a 
persistently elevated CRP. However, up to one third of patients with intestinal inflammation 
do not have an elevated CRP concentration.(9–11) In several studies assessing biologics such 
as TNF antagonists or ustekinumab, normalization of CRP concentrations reflected objective 
evidence of decreased inflammation and increased the likelihood of sustained remission on 
maintenance therapy or the likelihood of clinical relapse in case of a persistently elevated 
CRP.(12–14) In the ACCENT 1, 75% of patients with normalization of the CRP (<0.5mg/dL) 
at week 22 maintained remission over the study period.(15) Thus, changes in CRP 
concentrations provide useful information in monitoring response to treatment and the risk of 
further relapse in the two third of CD patients who have a raised CRP concentration in the 
presence of active disease.(9) 
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